The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
This new fund is amongst the largest for the sector in India
The plan is to advance innovative therapies to drug-resistant cancers
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
Subscribe To Our Newsletter & Stay Updated
